相关实验视频

Updated: Jul 6, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

免疫检查点抑制剂lirilumabb的活性和特异性的结构基础

Nicholas Lorig-Roach¹, Nina M Harpell¹, Rebecca M DuBois²

¹Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA, USA.

Scientific reports

|January 7, 2024

概括

这项研究揭示了lirilumab的精确结合部位,这是一种向自然杀手 (NK) 细胞的免疫检查点抑制剂. 了解KIR变异是提高NK细胞癌症免疫治疗疗效的关键.

科学领域:

免疫学免疫学免疫学
结构生物学结构生物学
癌症研究癌症研究

背景情况:

针对细胞毒性T细胞的免疫检查点抑制剂 (ICI) 在癌症治疗中取得了临床成功.
自然杀手 (NK) 细胞具有强大的抗癌活性,但NK细胞特异检查点抑制剂缺乏FDA批准.
利利鲁马布是一种NK细胞检查点抑制剂,向杀手性免疫球蛋白类受体 (KIRs),尚未证明确的临床疗效.

研究的目的:

为了阐明与KIR2DL3.3复合的lirilumab的晶体结构.
为了确定lirilumab的精确表观和KIR检查点封锁的分子机制.
研究人类KIR变异对lirilumab结合和临床疗效的影响.

主要方法:

进行X射线晶体学以确定与KIR2DL3.3结合的lirilumab的结构.
皮层映射用于确定lirilumab的结合部位.
具有约束力的研究,以评估KIR氨基酸变异对lirilumab相互作用的影响.

主要成果:

晶体结构揭示了KIR2DL3.3上利利卢马布的精确表位.
在表位内的关键氨基酸表现出种群级别的变化.
这些变化显著影响着利利鲁马布的结合亲和力.

结论:

对lirilumab-KIR相互作用的结构洞察力为了解检查点封锁机制提供了基础.
患者特异性的KIR变化可能会影响lirilumab在癌症免疫治疗中的临床疗效.
建立了开发新型NK细胞向免疫检查点抑制剂的可通用原则.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...